TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $23
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $23.
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $23.